Modulation of cell cycle progression by 5-azacytidine is associated with early myogenesis induction in murine myoblasts by A. Montesano et al.
Int. J. Biol. Sci. 2013, Vol. 9 
 
 
http://www.ijbs.com 
391 
International Journal of Biological Sciences 
2013; 9(4):391-402. doi: 10.7150/ijbs.4729 
Research Paper 
Modulation of Cell Cycle Progression by 5-Azacytidine 
Is Associated with Early Myogenesis Induction in Murine 
Myoblasts  
Anna Montesano 1, Livio Luzi 1, 2, Pamela Senesi 1, Ileana Terruzzi 3 
1. Department of Biomedical Sciences for Health, University of Milan, Milan, Italy. 
2. Metabolism Research Centre, San Donato Hospital and Scientific Institute, Milan, Italy. 
3. Division of Metabolic and Cardiovascular Science. Metabolism, Nutrigenomics and Cellular Differentiation Unit, DIBIT-San Raffaele 
Scientific Institute, Milan, Italy.  
 Corresponding author: Ileana Terruzzi. Division of Metabolic and Cardiovascular Science. Metabolism, Nutrigenomics and Cellular 
Differentiation Unit. DIBIT-San Raffaele Scientific Institute, Milan, Italy. e-mail: terruzzi.ileana@hsr.it 
© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ 
licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. 
Received: 2012.06.12; Accepted: 2013.02.19; Published: 2013.04.27 
Abstract 
Myogenesis is a multistep process, in which myoblasts withdraw from the cell cycle, cease to di-
vide, elongate and fuse to form multinucleated myotubes. Cell cycle transition is controlled by a 
family of cyclin-dependent protein kinases (CDKs) regulated by association with cyclins, negative 
regulatory subunits and phosphorylation. Muscle differentiation is orchestrated by myogenic 
regulatory factors (MRFs), such as MyoD and Myf-5. DNA methylation is crucial in transcriptional 
control of genes involved in myogenesis. Previous work has indicated that treatment of fibroblasts 
with the DNA-demethylating agent 5-azacytidine (AZA) promotes MyoD expression. We studied 
the effects of AZA on cell cycle regulation and MRFs synthesis during myoblast proliferation and 
early myogenesis phases in C2C12 cells. During the proliferation phase, cells were incubated in 
growth medium with 5µM AZA (GMAZA) or without AZA (GM) for 24 hours. At 70% confluence, 
cells were kept in growth medium in order to spontaneously achieve differentiation or transferred 
to differentiation medium with 5μM AZA (DMAZA) or without AZA (DM) for 12 and 24 hours. 
Cells used as control were unstimulated.   
In the proliferation phase, AZA-treated cells seemed to lose their characteristic circular shape and 
become elongated. The presence of AZA resulted in significant increases in the protein contents of 
Cyclin-D (FC:1.23 GMAZA vs GM p≤0.05), p21 (FC: 1.23 GMAZA vs GM p≤0.05), Myf-5 (FC: 1.21 
GMAZA vs GM p≤0.05) and MyoD (FC: 1.20 GMAZA vs GM p≤0.05). These results propose that 
AZA could inhibit cell proliferation. 
During 12 hours of differentiation, AZA decreased the downregulation of genes involved in cell 
cycle arrest and in restriction point (G1 and G1/S phase) and the expression of several cyclins, E2F 
Transcription Factors, cyclin-dependent kinase inhibitors, specific genes responsible of cell cycle 
negative regulation. During 24 hours of differentiation, AZA induced an increment in the protein 
expression of Myf-5 (FC: 1.57 GMAZA vs GM p≤0.05), MyoD (FC: 1.14 DM vs GM p≤0.05; FC: 
1.47 DMAZA vs GM p≤0.05), p21 (FC: 1.36 GMAZA vs GM p≤0.01; FC: 1.49 DM vs GM p≤0.05; 
FC: 1.82 DMAZA vs GM p≤0.01) and MyHC (FC: 1.40 GMAZA vs GM p≤0.01; FC: 2.39 DM vs GM 
p≤0.05; FC: 3.51 DMAZA vs GM p≤0.01). Our results suggest that AZA-induced DNA demeth-
ylation can modulate cell cycle progression and enhance myogenesis. The effects of AZA may open 
novel clinical uses in the field of muscle injury research and treatment. 
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Introduction 
Skeletal muscle differentiation is a multistep 
process that involves two simultaneous phenomena. 
The first is the induction of muscle-specific gene ex-
pression by myogenic regulatory factors (MRFs) such 
as Myf-5, MyoD, MRF4 and Myogenin. The second is 
the commitment of myogenic cells to skeletal muscle 
through irreversible withdrawal from the cell cycle, 
inducing permanent G1 phase [1-4]. Achievement of 
these two pathways is required for the formation of 
multinucleated myotubes. 
At the molecular level, several positive and neg-
ative cell cycle regulators have been identified [5]. 
Progression through the cell cycle phases is depend-
ent on consecutive activation and inhibition of phos-
phoproteins by cyclin-dependent kinases (CDKs) 
complexed with their activatory cyclins. These com-
plexes are in turn regulated by cyclin-dependent ki-
nase inhibitors (CKIs) [5]. 
Moreover, the members of E2F family of tran-
scription factors play a crucial role in the control of 
cell cycle progression and regulate the expression of 
genes required for the G1/S transition. These include 
genes encoding DNA replication proteins, enzymes 
involved in nucleotide synthesis and components of 
the origin recognition complex. E2F factors are con-
trolled by a number of mechanisms including nega-
tive check of their activity by Retinoblastoma protein 
(Rb), an important negative regulator of G1 progres-
sion [6-8]. 
During muscle differentiation, MRFs are ex-
pressed in a defined sequence: MyoD and Myf-5 are 
primarily expressed in proliferating, undifferentiated 
cells, whereas Myogenin expression is only induced 
upon muscle differentiation [6,7,9,10]. 
MyoD can promote cell cycle arrest by activation 
of the cyclin-dependent kinase inhibitor p21 [11], 
which inhibits a wide range of CDKs essential for cell 
cycle progression [12]. It is generally accepted that 
activation of p21 follows Myogenin expression during 
myoblast differentiation and that a high level of p21 is 
required to maintain the postmitotic cellular state. 
MyoD can also induce expression of Rb [13-15]. 
Other molecular signaling pathways such as the 
Ca++/calmodulin-dependent transcriptional path-
ways should also be considered as potential media-
tors of muscle growth and muscle hypertrophy. In 
skeletal muscle, an increase in intracellular Ca++ levels 
not only results in contractile activity, but is also re-
sponsible for muscle-specific gene expression through 
activation of downstream transcriptional pathways 
[16]. 
Calmodulin is a ubiquitous Ca++-binding protein 
expressed in all eukaryotic cells where it is involved 
in a variety of signaling pathways in a 
Ca++-dependent manner. Changes in intracellular 
Ca++ concentrations regulate the physiological activi-
ties of calmodulin. 
Ca++/calmodulin-dependent protein kinase II 
(CaMKII) is a multimeric serine/threonine kinase 
whose activity is detectable in skeletal muscle and 
requires binding of Ca++/calmodulin for its activa-
tion. Upon binding with Ca++/calmodulin, CaMKII is 
activated via autophosphorylation, then remains ac-
tive independent of Ca++ levels. In the cytoplasm, 
where the activated CaMKII is localized, signaling 
pathways that are mainly involved in mitochondrial 
biogenesis and expression of contractile proteins are 
induced [16]. 
Increasing evidence indicates that DNA methyl-
ation is an important mechanism underlying the cas-
cade of events that controls the process of muscle 
differentiation. The role of DNA methylation during 
myogenesis is not yet fully understood. Methylation 
of the 5´-position of cytosine in a CpG dinucleotide is 
an epigenetic mark commonly considered to mediate 
stable gene silencing [17-21], although the final effect 
strongly depends on CpG density.  
The relationship between DNA methylation and 
the activation of the myogenic program was first es-
tablished by the observation that treatment with the 
methyltransferase inhibitor, 5-aza-2´-deoxycytidine 
(AZA), converts C3H10T1/2 embryonic fibroblasts 
into muscle cells [18].  
In particular, the majority of epigenetic studies 
have focused on the role of histone modifications in 
genome reprogramming during myogenesis [22], 
while the role of DNA methylation is less well estab-
lished. 
Data reported in literature are concerned with 
the role of DNA methylation in myogenic lineage 
acquisition [18-21,23,24] and MRFs expression [25-27]. 
Only in the last year, the study performed by 
Hupkes et al. [28] has demonstrated that genomic 
demethylation following treatment with AZA 
strongly enhances C2C12 maturity. This was the first 
work in which there was a global analysis of the ef-
fects of DNA demethylation during muscle differen-
tiation (gene expression in myogenic differentiation, 
functional and contractile activity, calcium uptake, 
sarcomeric morphology and development). However, 
this work did not show any specific evidence of the 
role of DNA demethylation in cell cycle control, in 
myogenic regulator factors expression and in differ-
entiation induction. 
5-aza-2'-deoxycytidine (AZA) was originally 
developed as an antitumor agent. It has cytotoxic ef-
fects if used in pharmacological treatments but it can 
also induce differentiation in several experimental 
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systems, most notably induction of muscle, adipo-
cytes and chondrocytes in cultures of drug-treated 
mouse embryo fibroblasts [18,19]. The mechanisms 
underlying this drug-induced differentiation have 
been difficult to unravel [23]. As a demethylating 
agent, AZA has been extensively used in epigenetic 
research. It is incorporated into DNA where it binds 
DNA methyltransferase (DNMT) in an irreversible, 
covalent manner, thus sequestering the enzyme and 
preventing maintenance of the methylation state 
[29-31]. 
The immortalized murine C2C12 myoblastic cell 
line provides a good in vitro model for the major steps 
of myoblast proliferation and differentiation, being 
easily reproducible in cell culture [32-35]. 
In this cellular model, undifferentiated my-
oblasts are recognizable as flat, fusiform or 
star-shaped cells, which appear scattered on the sub-
strate and are consistently mononucleated. After 
reaching confluence or 24 hours after serum removal, 
C2C12 cells are considered myoblasts in an early dif-
ferentiation stage and they are characterized by a 
change in orientation, as well as by cell lengthening 
and thickening. Later, confluent mononucleated my-
ocytes begin to fuse to form multinucleated myotubes 
(intermediate differentiation), which are positive for 
the characteristic muscle-specific protein MyHC 
(Myosin Heavy Chain). Myotubes become wider and 
longer over the next few days as additional myocytes 
fuse (late differentiation). Multinucleated and large 
myotubes appear to form a network with numerous 
nuclei arranged in multiple linear arrays (late differ-
entiation). As occurs in vivo, C2C12 myoblastic dif-
ferentiation is driven by activation of muscle-specific 
genes. 
We used this cell line as a model for cell cycle 
withdrawal accompanying cellular differentiation. To 
gain further insight into the role of DNA methylation 
in cell cycle progression and in the induction of the 
process of muscle differentiation, we examined the 
action of AZA on the regulation of the cell cycle and 
MRFs synthesis during myoblast proliferation and 
early myogenesis phases in the C2C12 cell line (Fig. 1). 
Materials and Methods 
Materials 
Mouse C2C12 myoblastic cells were purchased 
from the European Collection of Animal Cell Cultures 
(ECACC). Reagents were purchased from Sigma 
Chemical Co. (St. Louis, MO, U.S.A.) Primary anti-
bodies : anti-MyoD (C-20), anti-Myf-5 (C-20), an-
ti-MyHC (H-300), anti-p21 (C-19), anti-Cyclin B1 
(H-433), anti-Cyclin D1 (C-20), anti α−Tubulin (TU-02) 
and anti-Calnexin (H-70). Monoclonal or polyclonal 
primary antibodies and peroxidase-conjugated sec-
ondary antibodies for Western Blot analysis and 
Rhodamine-conjugated antibodies for Immunofluo-
rescence analysis were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, U.S.A.). 
Experimental procedures 
C2C12 skeletal myoblastic cells were routinely 
maintained at 37°C in a humidified atmosphere con-
taining 5% CO2 in a growth medium comprising 
Dulbecco’s Modified Eagle’s Medium (DMEM) sup-
plemented with 20% (v/v) fetal bovine serum (FBS), 
1% penicillin-streptomycin and 1% L-glutamine up to 
70% of confluence. During this phase, representing in 
this study the proliferation phase, cells seeded at 
6X102 cells/cm2 were maintained in mitogen-rich 
growth medium (GM) as single myoblasts. These 
proliferating cells were treated with AZA (5 μM) for 
24 hours to induce DNA demethylation, or not treated 
with AZA. 
The AZA concentration of 5 μM has been re-
ported to be the optimal concentration to induce ef-
fects on the differentiation process without cytotoxi-
city [23,28], as validated in our dose-response exper-
iments (data not shown). 
 
 
Figure 1. Study plan. Simplified scheme of cell treatments and time points during the proliferation phase and early differentiation phase. 
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C2C12 myoblasts spontaneously fuse and dif-
ferentiate into multinucleated myotubes as a result of 
both the achievement of confluence (as in the case of 
cells maintained in growth medium with 20% FBS: 
GM) and the removal of the serum growth factors (as 
in the case of cells transferred in DMEM supple-
mented with 1% Horse Serum: DM). 
At 70% confluence cells were maintained in GM 
in order to spontaneously achieve differentiation or 
transferred in DM both and without AZA (GM,DM) 
or with 5 μM AZA (GMAZA, DMAZA) for 12 and 24 
hours. 
The medium was changed every day. Under 
these conditions myoblasts are known to exit the cell 
cycle and commit to the myogenic lineage [36]. 
To ensure reproducibility, for all experiments 
cultures were grown for a period no longer than 6 
weeks after recovery from frozen stocks. 
Growth curve 
C2C12 myoblasts were plated on 60x15-mm 
culture dishes at 40% confluence and grown in the 
presence of GM supplemented with AZA (5 µM) or 
without AZA. The experiment was continued until 
subconfluence was achieved in the control cells (3 
days), and the medium was changed every 24 hours. 
Daily during the culture period one cell plate per 
condition was trypsinized and the cells counted using 
a hemocytometer. The average number of cells for 
each day was then calculated and the values were 
used to plot growth curves for myoblasts treated with 
AZA and control cells without AZA (growth control 
GM and differentiation control DM). In addition, 
morphological changes were evaluated daily.  
Electrophoretic techniques and immunoblot-
ting analysis 
C2C12 cells were homogenized in lysis buffer (50 
mM Tris/HCl, pH 7.4, 150 mM NaCl, 1% Triton 
X-100, 1 mM sodium orthovanadate (Na3VO4), 1 mM 
EDTA, 1 mM PMSF, 1 mg/ml aprotinin, 1 mg/ml 
leupeptin, 1 mg/ml pepstatin) and shaken for 1h at 
4°C. Detergent-insoluble material was removed from 
the cell suspension by centrifugation at 12,000 x g for 
30 min. Protein contents were determined using the 
Bradford method. The proteins in 30-µg aliquots of 
supernatant from the different samples were resolved 
by SDS-PAGE. Electrophoresed proteins were trans-
ferred to nitrocellulose membrane (Protran®, What-
man ® Schleicher & Schuell) as described previously 
[37]. The membranes were incubated with specific 
primary antibodies and then incubated with 
HRP-conjugated secondary antibodies. Immunoreac-
tive bands were visualized by an enhanced chemilu-
minescence method (Amersham Pharmacia Biotech: 
Piscataway, NJ, USA). The membrane was stripped 
and reprobed with an antibody to calnexin or 
α-tubulin to confirm equal protein loading per sam-
ple. The immunoreactive bands were measured 
quantitatively by densitometric analysis using Scion 
Image Software (Scion Corporation, Frederick, MD, 
USA).  
The data are presented as fold changes (FC) in 
relation to the controls. 
Immunofluorescence analysis 
For indirect Immunofluorescence, cells were 
fixed with 4% paraformaldehyde, permeabilized with 
0.2% Triton X-100, and blocked with phos-
phate-buffered saline containing 1% bovine serum 
albumin. Cells were then immunostained with Rho-
damine-conjugated antibodies (Santa Cruz Biotech-
nology, California, USA) and the nuclei revealed with 
DAPI staining. Cells were viewed by fluorescence 
microscopy (Leica DM IRE2) and images of myotubes 
were captured using IM50 software (Leica Microsys-
tems, Switzerland) for size comparison. Data were 
displayed and analyzed using Adobe® Photoshop® 
CS4.  
RT-PCR array analysis 
Gene expression levels were assessed by RT2 
Profiler PCR Arrays RT-PCR system (SABiosciences 
Corporation, Frederick, MD 21703 USA). Cell Cycle 
RT2 Profiler PCR Arrays plates were used to analyze a 
panel of genes simultaneously. We studied the ex-
pression of the following genes during G1 phase and 
the G1/S transition: Calcium/Calmodulin-dependent 
protein kinase II alfa (Camk2a) and beta (Camk2b); 
Integrin beta 1 (Fibronectin receptor beta Itgb1); Nu-
clear Factor of activated-T cells, cytoplasmic, cal-
cineurin-dependent 1 (Nfact1). 
We also studied the expression of the following 
genes involved in the cell cycle checkpoint: Caspase 3 
(Casp3); CDK5 regulatory subunit associated protein1 
(Cdk5rap1); Cyclin-dependent kinase inhibitor 1a 
(Cdkn1a or p21) and Cyclin-dependent kinase inhib-
itor 1b (Cdkn1b); Growth arrest and 
DNA-damage-inducible 45 alpha (Gadd45a); Tumor 
susceptibility gene 101 (Tsg101); Cyclin A1 (Ccna1), 
Cyclin A2 (Ccna2), Cyclin B1 (Ccnb1) and Cyclin B2 
(Ccnb2); E2F Transcription Factor E2f1, E2f2, E2f3, 
E2f4. 
In addition, we evaluated the expression of the 
following genes implicated in negative regulation of 
the cell cycle: Retinoblastoma-like1 and Retinoblas-
toma-like 2 (Rbl1 and Rbl2); Transformation related 
protein 53 (Trp53). 
GADPH and Actin housekeeping gene were in-
cluded as endogenous normalization controls. 
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Total RNA was isolated from C2C12 cells using 
the RNeasy Plus Mini Qiagen kit (Qiagen, Germany) 
according to the manufacturer’s instructions. Total 
RNA (1 µg) was reverse-transcribed using the RT2 
First Strand kit (SABiosciences). The reverse tran-
scripts were used as templates for analysis of gene 
expression level using Superarrays Cell Cycle RT2 - 
PCR Arrays RT2 - PCR Arrays plates according to the 
manufacturer’s instructions. Each sample was run in 
triplicate. The expression level of the housekeeping 
genes chosen for normalization in the threshold cycle 
(Ct) for each experimental condition and then the fold 
change (ΔΔCt) for each gene for the treated group 
compared to the control group were calculated. If 
ΔΔCt is greater than 1, the result may be reported as a 
fold upregulation. If ΔΔCt is less than 1, the result may 
be reported as a fold downregulation. 
Statistical analysis  
All experiments were performed three times. For 
immunoblotting and immunofluorescence analysis, 
statistical evaluation was performed using an un-
paired t-test. Data are presented as means ± SD. Re-
sults were considered statistically significant if p≤0.05. 
Results 
We first evaluated the effect of AZA-induced 
demethylation on the proliferation phase (Fig. 2A). 
The cell growth curves showed that C2C12 cells grew 
slowly during the first 2 days of culture, while cell 
numbers increased more rapidly during the third day. 
AZA treatment induced a decrease in cell division in 
relation to the untreated control (GM) cells (Day 2: 
GMAZA vs GM p≤0.05; DM vs GM p≤0.01. Day 3: 
GMAZA vs GM p≤0.05; DM vs GM p≤0.01). Cells 
treated with GMAZA showed a growth trend similar 
to cells maintained in DM medium, in respect to GM 
control cells, indicating the potential ability of AZA to 
modify cell growth, promoting proliferation arrest. 
Very important support for these findings was 
the morphological change observed in AZA-treated 
cells during the proliferation phase: the cells appeared 
to lose their characteristic circular shape (Fig. 2B, GM) 
and become elongated (Fig. 2B, DM and GMAZA). 
Phase contrast images obtained on day 3 of prolifera-
tion confirmed comparable morphological changes in 
the DM and GMAZA conditions. 
Taken together, these results suggest that AZA 
could be able to promote the induction of differentia-
tion by decreasing the rate of cell growth and causing 
the acquisition of a specific myocyte phenotype. 
The expression of Cyclin D is induced during 
differentiation [7,38,39], in contrast to most cyclins 
[7,40].  
 
Figure 2. Growth curve and morphological study. A) C2C12 proliferation rate through kinetics of cell growth curve analysis. Proliferation curve 
shows that AZA treatment induces a decrease of cell division in respect to untreated control cells. (Day 2: GMAZA p≤0.05; DM p≤0.01; Day 3: GMAZA 
p≤0.05; DM p≤0.01 ). GMAZA cells reveal a growth trend similar to that of DM cells. Significance: * p≤0.05, ** p≤0.01. B) Evaluation of cells morphology. 
Morphological changes are apparent in DM cells and AZA-treated cells on day 3 during the proliferation phase. The cells have lost their characteristic 
circular shape and have become elongated in contrast to control cells (GM). 
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To determine AZA effects on regulators of cell 
cycle withdrawal during proliferation, we measured 
the protein contents of cell cycle regulators (Cyclin B1, 
Cyclin D, p21) and early myogenic regulatory factors 
(Myf-5 and MyoD). AZA stimuli resulted in signifi-
cant increase in the protein amount of: Cyclin D (FC: 
1.23 GMAZA vs GM p≤0.05), p21 (FC: 1.23 GMAZA 
vs GM p≤0.05), Myf-5 (FC: 1.21 GMAZA vs GM 
p≤0.05) and MyoD (FC: 1.20 GMAZA vs GM p≤0.05). 
However, in the presence of AZA there was no sig-
nificant detectable rise in the levels of Cyclin B (Fig. 
3A,B,C,E,F).  
To confirm the absence of an AZA-mediated 
apoptotic action on proliferating C2C12 cells, we 
measured p53 protein levels. The p53 regulator is 
known to play a key role in growth arrest and apop-
tosis after cell stress [41]. AZA-treated cells showed a 
p53 protein content comparable to that of GM cells 
(Fig. 3D). 
As shown in DAPI Immunofluorescence images 
(Fig. 3G), obtained during the first day of growth 
curve, after 24 hours of proliferation, cells densities in 
the GM and GMAZA conditions were superimposa-
ble. This finding is additional proof of the absence of 
an AZA-mediated apoptotic action.  
Fig. 3G shows Immunofluorescence images of 
Myf-5 and MyoD expression in AZA-treated cells 
obtained after 24 h of proliferation during the first day 
of growth curve and at 40% cell confluence.  
The AZA-treated cells validate the morphologi-
cal changes previously described. 
The GMAZA treatment revealed a major number 
of cell positive for MyoD and Myf-5 in respect to the 
GM control, and this could indicate that the differen-
tiation process began earlier than in the untreated 
cells (GM).  
Given the effect of AZA on the proliferation 
phase, we wanted to study its effects on the subse-
quent early stage of differentiation (12-24 hours after 
differentiation induction, Fig. 1). 
To verify the hypothetical role of AZA on global 
cell cycle gene expression, we performed quantitative 
RT-PCR 12 hours after the start of differentiation in 
C2C12 cells (Fig. 1), in both GM and DM conditions. 
We wanted to analyze the action of AZA in terms of 
the number of cell cycle genes regulated over time. 
Fig. 4A shows that in AZA-treated cells a larger 
number of cell cycle genes were regulated than in 
untreated cells. 
 
 
Figure 3. Key cyclins and myogenic protein levels in proliferation phase (Day 1, 24 h proliferation, 40% cell confluence).  A) Protein levels 
of cell cycle regulators during proliferation phase. In GMAZA conditions the graphs show a negligible effect on Cyclin B protein levels. B) Protein levels of 
cell cycle regulators during proliferation phase. In GMAZA conditions the graphs illustrate a significant increase in Cyclin D protein amount (p≤0,05) in 
respect to control (GM). C) Protein levels of cell cycle regulators during proliferation phase. GMAZA conditions shows a significant rise in p21 protein 
content in respect to GM (p≤0,05). D) Apoptotic marker p53 protein levels during proliferation phase. The graph shows no differences between GMAZA 
treatment and control. E) Protein levels of early MRFs during proliferation phase. AZA treatment seems to cause a significant raise in MyoD protein levels 
in respect to control (p≤0,05). F) Protein levels of early MRFs during proliferation phase. AZA significant increases Myf5 protein levels in respect to control 
(p≤0,05). G) Myf-5 and MyoD immunofluorescence images in proliferation phase. The images show a major density of MyoD (up panel) and Myf-5 (down 
panel) positive cells (red) in GMAZA condition respect to control (GM). Representative DAPI images of GM and GMAZA conditions during the prolif-
eration phase (fist day of growth curve, 24 h proliferation) are also shown.  A-F Insets representative immunoblots of analyzed proteins. 
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Figure 4. Cell cycle RT-PCR ARRAY analysis (Early Differentiation, 12 h after the start of differentiation). A) Global gene expression 
analysis in early differentiation. Each area in the graphic represents the number of genes regulated in time after 12 hours of differentiation induction. In 
AZA-treated cells several cell cycle genes are regulated compared to untreated cells. B) Expression analysis of cell cycle regulating genes in early dif-
ferentiation (12 hours). The figure shows the expression analysis of genes involved in cell cycle and arrest restriction point. AZA treatment decreases the 
downregulation of these genes promoting myoblast differentiation. C) Expression analysis of Cyclins and E2F Transcription Factors genes in early dif-
ferentiation (12 hours). The figure shows the expression analysis of Cyclins and E2F Transcription Factors genes. AZA treatment slightly decreases the 
downregulation of these important regulators of cell cycle progression. D) Expression analysis of cell cycle negative regulators genes in early differentiation 
(12 hours). Array panel shows the significant AZA-induced downregulation decrease in the expression of specific genes responsible of negative regulation 
of cell cycle. 
 
In detail, RT-PCR illustrated that AZA decreased 
the downregulation of genes involved in cell cycle 
arrest including Caspase 3 (Casp3), Cdk5 regulatory 
subunit associated protein1 (Cdk5rap1), Growth ar-
rest and DNA-damage inducible 45 alpha (Gadd45a), 
Tumor susceptibility gene 101 (Tsg101). This effect 
was particularly relevant for genes modulating the 
cell cycle restriction point (G1 and G1/S phase) when 
cells are committed to continue in the cell cycle (pro-
liferate) or exit from the cell cycle (differentiate) [41]. 
AZA also decreased the downregulation of Calci-
um/Calmodulin-dependent protein kinase 2 alpha 
(CamK2a), Calcium/Calmodulin-dependent protein 
kinase 2 beta (CamK2b), Integrin beta 1 (Itgb1), Nu-
clear factor of activated T-cells, cytoplasmic, calcineu-
rin-dependent 1 (Nfact 1) genes too (Fig. 4B). 
In order to obtain supplementary information 
relating to cell cycle progression, we analyzed gene 
expression of some important cyclins and E2F Tran-
scription Factors. 
The expression of most cyclins appeared to be 
rapidly suppressed with the onset of differentiation 
when cells are blocked in G1 phase [7,40]. Fig. 4C 
shows that AZA induced a slight reduction in the 
downregulation of the expression of several cyclins 
(Ccna1, Ccna2, Ccnb1, Ccnb2) and E2f 1,2,3,4 Tran-
scription Factors. 
The expression of positive regulators of cell cycle 
progression, Cyclins and Cyclin-dependent kinase 
(CDKs), is regulated at several levels during early 
differentiation. In particular, expression of some 
CDKs drops during differentiation [7,42,43]. 
In contrast, the expression levels of Cy-
clin-dependent kinase inhibitors (CKIs) important for 
in vitro and in vivo myoblast differentiation, increase 
during differentiation [7,44,45]. 
AZA decreased the downregulation of Cy-
clin-dependent kinase inhibitor 1A (Cdkn1A) also 
known as p21, and of Cyclin-dependent kinase inhib-
itor 1B (Cdkn1b) (Fig. 4D). 
A close association between cell cycle arrest and 
induction of myogenic differentiation has also been 
shown by the activity of proliferative negative regu-
lators. In particular, data in the literature emphasize 
the mutual activity of p21 and Rb in early differentia-
tion that maintains a postmitotic state by ensuring the 
absence of DNA replication [46]. 
Furthermore, Fig. 4D shows that AZA treatment 
decreased the downregulation of specific genes that 
negatively regulate the cell cycle including Reti-
noblastoma-like 1 (Rbl1), Retinoblastoma-like 2 
(Rbl2), Transformation related protein 53 (Trp53). 
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These data suggest that AZA could have a nega-
tive effect on cell cycle progression promoting cell 
cycle arrest. 
In order to further validate our hypothesis, we 
performed Western Blot analysis in C2C12 cells after 
24 hours of differentiation, in both GM and DM (Fig. 
1). We evaluated the expression levels of key proteins 
involved in cell cycle progression and early differen-
tiation. 
Differentiation process requires the upregulation 
of MyoD and Myf-5 [2,6,7,9,10]. 
As shown in Fig. 5A, only GMAZA condition 
showed a significant increase in Myf-5 protein content 
(FC: 1.57 GMAZA vs GM p≤0.05). DM and DMAZA 
conditions did not show significant increases in Myf-5 
expression. In contrast to the expression of Myf-5, 
significantly higher levels of MyoD expression were 
seen in DM and DMAZA conditions in respect to GM 
(FC: 1.14 DM vs GM p≤0.05; FC: 1.47 DMAZA vs GM 
p≤0.05). In fact at 24 hours the level of expression of 
MyoD was delayed compared to that of Myf-5 and 
was not significantly different in GM and GMAZA, 
but occurred earlier in DM and DMAZA conditions in 
which differentiation was accelerated. 
Increases in p21 protein levels were seen after 24 
hours of differentiation (Fig. 5C) (FC: 1.36 GMAZA vs 
GM p≤0.01; FC: 1.49 DM vs GM p≤0.05; FC: 1.82 
DMAZA vs GM p≤0.01). 
As expected, a substantial raise in the amount of 
MyHC was seen in AZA-treated cells (FC: 1.40 
GMAZA vs GM p≤0.01; FC: 2.39 DM vs GM p≤0.05; 
FC: 3.51 DMAZA vs GM p≤0.01) confirming the role 
of AZA on the myogenic process. 
Finally, Immunofluorescence analysis after 24 
hours of differentiation (Fig. 6) revealed the presence 
of a major number of MyHC-positive cells in GMAZA 
and DMAZA conditions in contrast to the number in 
untreated cells (GM and DM). This effect was not 
caused by differences in cell density, since DAPI im-
aging showed that cell numbers under all conditions 
were superimposable. 
Morphological changes in AZA-treated C2C12 
cells were observed (Fig. 6). 
 
Figure 5. Key myogenic protein expression in early differentiation (24 h after differentiation induction). A) Immunoblot shows that only 
GMAZA condition showed a significant increase in Myf-5 protein content (GMAZA vs GM p≤0.05). DM and DMAZA conditions did not show a significant 
increment of Myf-5 expression. B) The bar graph shows a significant higher level of MyoD expression in DM and DMAZA conditions respect to GM (DM 
vs GM p≤0.05; DMAZA vs GM p≤0.05). C) Immunoblot showed the increase of p21 protein level at 24 hours of differentiation (GMAZA vs GM p≤0.01; 
DM vs GM p≤0.05; DMAZA vs GM p≤0.01). D) Immunoblot showed an important increment in MyHC content in AZA-treated cells (GMAZA vs GM 
p≤0.01; DM vs GM p≤0.05; DMAZA vs GM p≤0.01).  Representative immunoblots of analyzed proteins are shown on the graphic. Significance: * p≤0.05, 
** p≤0.01. 
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Figure 6. MyHC immunofluorescence analysis in early differentiation (24 hours after differentiation start). Immunofluorescence analysis at 
24 hours of differentiation reveals the presence of a major number of MyHC positive cells (red) in GMAZA and DMAZA conditions in respect to untreated 
cells (DM and GM). Moreover, in GMAZA and DM conditions myoblasts are becoming elongated in respect to GM. This behavior is particularly noticeable 
in DMAZA condition, in which confluent mononucleated myocites began to fuse to form multinucleated myotubes. Insets representative DAPI images of 
all conditions collected at 24 hours of early differentiation were added to confirm comparable cell densities. 
 
Figure 7. Transcription factors regulating different stages of myogenesis and AZA action. Schematic illustration of skeletal muscle differen-
tiation and AZA effects. The committed myoblasts exit cell cycle, cease to divide and begin to elongate (early differentiation). In a second stage mono-
nucleated myocytes begin to fuse forming multinucleated myocites (intermediate differentiation) which become wider and longer and start to organize into 
multinucleate myotubes (late differentiation). Cell cycle withdrawal and each phase of differentiation is orchestrated by activation of specific Cyclins, CDKs, 
CDKi and muscle regulatory factors which lead to the induction of specific muscle proteins as shown in the lower portion of the figure. During the 
proliferation phase, AZA could cause a cut in cell division and a decreased growth trend. Furthermore, AZA seems to anticipate early MRFs protein 
expression. During early differentiation AZA may also be able to induce protein expression of early MRFs, p21 and muscle specific protein MyHC, marker 
of differentiation. 
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In the AZA and DM conditions myoblasts 
started to become elongated in contrast to their shape 
in GM. This was particularly evident in DMAZA 
condition, in which confluent mononucleated myo-
cytes began to fuse to form multinucleated myotubes. 
Taken together, these results appear to support 
our hypothesis that, in vitro, AZA causes cell cycle 
withdrawal and enhances myogenic progression in 
C2C12 cells. 
Discussion 
Myogenesis is a multistep process orchestrated 
by an ordered and sequential expression of muscle 
regulatory protein and transcription factors. The 
muscle-specific gene program is governed by a com-
bination of genetic and epigenetic events that affect 
the satellite cells switching them from a quiescent to 
an activated state [1-4,6,7,9,10]. 
An epigenetic mechanism is DNA methylation, 
considered a mark leading to gene silencing and act-
ing as a switch capable of turning on or off the ex-
pression of genes regulating all cellular processes in-
cluding development and differentiation [17,47,48]. 
It is well known that DNA methylation and 
myogenesis are linked [22,27,28]. 
The first evidence that DNA demethylation 
plays a role in myogenesis regulation was the finding 
that muscle differentiation is induced in fibroblast 
treated with AZA, a potent demethylating agent 
[18,49]. 
Our previous results indicate that DNA hypo-
methylation induces the activation of factors pro-
moting myoblast proliferation and differentiation and 
then muscle growth [50]. 
The effects of AZA on changes in gene expres-
sion patterns are due to its ability to inhibit DNA 
methyltransferases. For this reason we chose to study 
the effects of AZA on C2C12 myoblasts that are a 
good model of muscle differentiation. 
Proliferation and differentiation are mutually 
exclusive processes in myogenesis.  
Proliferation of undifferentiated myoblasts 
ceases in response to the downregulation of Cyclin D1 
expression, thus promoting cell cycle exit and allow-
ing muscle differentiation to start [7]. 
Investigating the effect of AZA on the growth 
capacity of C2C12 myoblasts, we observed the ability 
of this DNA-demethylating agent to reduce cell pro-
liferation leading to cell cycle arrest, as occurs with 
growth factors removal (DM condition). In support of 
this, cell growth curves showed the ability of AZA to 
interrupt proliferation. The demethylation effects 
were visible not only in the kinetics of cell growth, but 
also in the morphological analysis: AZA-treated cells 
appeared to lose their original circular shape to 
achieve a new, specific, elongate morphology, typical 
of muscle phenotype. Morphological changes ob-
served in DM and GMAZA treated cells were su-
perimposable showing that, under these two condi-
tions, differentiation was faster than in the control 
condition, in which differentiation was determined 
only by cell contact. This suggests that the presence of 
AZA may favor more rapid differentiation.  
Since activation of the muscle differentiation 
program requires irreversible cell cycle withdrawal 
and tissue-specific gene expression, we then investi-
gated the effect of AZA on the exit of C2C12 myoblast 
from the cycle. Our results confirmed that the expres-
sion level of genes including p21, required to maintain 
the postmitotic cellular state, and Cyclin D, whose 
expression is induced during differentiation, in-
creased after AZA treatment. 
Similarly, the expression levels of MyoD and 
Myf-5 transcription factors, myogenic markers al-
ready expressed in undifferentiated proliferating 
myoblasts, were increased after AZA treatment.  
Also during the early phase of differentiation, 
AZA was found to have a negative effect on cell cycle 
progression, promoting the arrest of cell proliferation. 
In fact, AZA stimuli seem to cause a considerable 
downregulation of the expression of genes implicated 
in cell cycle checkpoint, arrest and negative control. 
The effects of AZA on mRNA expression of 
genes involved in cell cycle arrest was also confirmed 
by determining the protein content of cell cycle regu-
lators and early myogenic regulatory factors.  
Our results demonstrated that only GMAZA 
condition showed a significant increase in Myf-5 pro-
tein content. DM and DMAZA conditions did not 
show a significant increase in Myf-5 expression 
probably because the removal of serum growth fac-
tors and AZA treatment, which accelerated the dif-
ferentiation process, led to Myf-5 expression earlier 
than in GM. There is also some evidence that Myf-5 
expression upregulates the expression of MyoD, 
driving exit from the cell cycle towards myogenic 
differentiation. 
This could explain the significantly higher level 
of MyoD expression, in contrast to Myf-5 expression, 
in DM and DMAZA conditions in respect to GM. In 
fact at 24 h its expression, which was delayed com-
pared to that of Myf-5, was not significantly different 
in GM and GMAZA, but occurred earlier in DM and 
DMAZA, in which differentiation is accelerated. 
These data support our hypothesis that AZA 
induces the expression of genes related to muscle 
differentiation at an early time point, when cell fusion 
has not yet taken place. 
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Surprisingly p21 protein levels and MyHC con-
tent showed an important rise after 24 hours of dif-
ferentiation, occurring earlier than MyoD expression. 
Such an event may be explained by the possibil-
ity that AZA treatment induces the expression of 
genes essential to cell cycle arrest and the drive to-
wards differentiation, without following the ordered 
and sequential expression of the muscle-specific gene 
program. In relation to our findings, this could mean 
that p21, principal factor responsible for cell cycle 
withdrawal, and MyHC, the first marker of muscle 
phenotypic differentiation, are AZA-specific targets. 
If this hypothesis will be confirmed, AZA would 
represent a topic drug for the treatment of disease in 
which p21 or MyHC expression are directly compro-
mised (some forms of myopathy and hypertrophic 
cardiomyopathy). 
Moreover, AZA seemed to induce cell morpho-
logical changes during early differentiation phases 
and demethylation could have positive effects on 
MRFs and muscle-specific MyHC protein expression 
during acquisition of the commitment to the myo-
genic lineage.  
These results suggested that AZA not only sup-
presses proliferation but also causes elongation and 
fusion of myoblasts. 
The study of MRFs activity regulation may have 
important implications in understanding the mecha-
nisms underlying several myopathies and regulating 
muscle growth and tissue regeneration. Our results 
seem to confirm that AZA-induced demethylation is 
involved in myoblast determination after specific 
control of cell cycle progression.  
In summary, our findings suggest that the se-
quence of events following treatment with AZA re-
sults in improved maturity of C2C12 myotubes. First, 
this DNA methylation inhibitor promotes an in-
creased expression of checkpoint genes involved in 
cell cycle progression and arrest, and upregulation of 
key myogenic transcription factors. 
The present results may propose novel clinical 
uses for AZA which is presently used in the clinic for 
its antineoplastic effects only. Our in vitro studies 
may constitute novel proof of principle for the poten-
tial use of the compound in the treatment of serious 
clinical conditions characterized by reduced or func-
tionally impaired muscle mass for its ability to pro-
mote the formation of new muscle. 
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